seeding the future of monoclonal antibodies bioproduction

Plant-based Antibodies

Our vision is simple: reduce health inequalities on the planet in a sustainable way, and therefore take action for the United Nations sustainable development goals. We believe the next generation of medicines should be efficient and affordable worldwide.

/ 01

mission

Develop and mass produce plant-based antibodies

Plantibodies is a unique biotech company dedicated to the development and production of plant based monoclonal antibodies to cure life threatening diseases such as cancers, neurodegenerative diseases, and autoimmune diseases.

Situation: The number of patients who suffer from cancer, neurodegenerative diseases, and pathogenic infections is rising steadily. For example, in the US over 1.7 million people are diagnosed with cancer each year.

Biologics are complex drugs that cannot easily be synthesised using classical chemistry technologies, and that are usually produced by living organisms such as mammalian cells.

Bioproduction challenges: The current monoclonal antibodies bioproduction methods encouter several problems such as:

  • High cost of treatments, sometimes exceeding $100K of treatment per patient per year
  • Risks of transmission of pathogenic contaminants to patients
  • Expensive and limited scale-up capacity
  • Use of animals origin reagents

Solution: Plantibodies proposes to solve these problems by using the plants to produce monoclonal antibodies. This will reduce the initial capital investment and lower operational costs, while improving safety. Furthermore, using biodegradable plant-based expression systems allows to reduce ecological footprint through inherent carbon dioxide fixation and improved fertilizer use, to harvest side stream additional products, and to use less glucose and Fetal Bovine Serum while expanding treatment access.

Opportunity: Over the next years many monoclonal antibodies patents will expire, creating new opportunities for the manufacture of biosimilar antibodies. 

Products: Our plant-based antibody production platform produces original and biosimilar monoclonal antibodies.

/ 02

Technology

cheaper, safer, and more stable antibodies

Plantibodies company combines the latest advances in (1) synthetic biology, (2) plant biology, and (3) molecular biology, to bioproduce antibodies from plants.

The concept is simple:

  • Design and produce synthetic DNA vectors coding for the targeted humanized monoclonal antibody to produce
  • Insert gene into plants
  • Grow plants under a BSL2 greenhouse. Plants will produce monoclonal antibodies in their leaves
  • Harvest plants and grind the leaves
  • Purify to obtain a purified solution of monoclonal antibodies

Over the last years, Plantibodies team has screened several plants to find the most appropriate for monoclonal antibodies production. We optimized plant transformation to increase yields and get desired structure with glycoengineering techniques.

With an achieved yield of 4 to 5g of antibody per kilo of plant, Plantibodies can reduce upstream production costs by 90%.

Thanks to our patented core technlogies, know how and expertise, our antibodies can be produced without vertebrate pathogen. 

/ 03

OPERATIONS

an agile biotech company based in Paris (France)

Plantibodies HQ are based in Paris 5th district. Our team works in close collaboration with PSL University and Sorbonne University, and is a member of Medicen Paris Region as well as France Biotech networks. You can find our offices at Pépinière 27 (Paris 11th), and our lab and facilities at GreenLab (Paris 5th). Plantibodies is supported by BPI France and has received the DeepTech label.

We are currently working on R&D and preclinical studies of 4 biosimilars. For more information, please contact us.

/ 04

team

Highly qualified and innovation driven

From France’s top research bioscience institutions as well as business schools, Plantibodies team has coalesced around the vision of creating plant-based antibodies that urgently need to be released onto the market, especially in developing countries. 

Pierre BAUËR, Co-founder -CEO

Broadly trained in science (Engineer, PhD) and business (MBA)

BILAL MAZHAR, co-founder -cso

PhD in molecular biology at College de France (2019).

Jessica APULEI, CTO

PhD in neuroscience and pathology at College de France (2019).

Won KIM, co-founder -advisor

PHD and MBA, professor at ESCE, Paris business school.

/ 05

Supports

a highly innovative ecosystem
en_USEnglish